证券代码：300294 证券简称：博雅生物 公告编号：2025-075 华润博雅生物制药集团股份有限公司 （一）投资目的 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 为合理利用闲置自有资金，提高自有资金使用效率和收益，在保障华润博雅 生物制药集团股份有限公司（以下简称公司）正常运营的情况下，公司于2025 年10月27日召开第八届董事会第十六次会议、第八届监事会第十三次会议，审议 通过《关于使用部分闲置自有资金进行现金管理的议案》，公司拟使用不超过人 民币260,000.00万元的闲置自有资金进行现金管理，以实现资金收益，上述额度 可滚动使用，管理期限自董事会审议通过之日起12个月内有效。公司监事会对该 事项发表了意见。现将有关情况公告如下： 一、投资概况 （四）资金来源 公司阶段性的闲置自有资金。 （五）实施方式 1、公司董事会授权公司法定代表人在前述额度范围内选择适当的时机及合 适的产品，选择一家或多家金融机构进行合作并签署相关法律文件（包括但不限 于理财产品购买协议、风险承诺书等）； 2、授权期限自董事会审议通过 ...

证券代码：300294 证券简称：博雅生物 公告编号：2025-076 为合理利用闲置募集资金，提高募集资金使用效率和收益，在保障华润博雅 生物制药集团股份有限公司（以下简称公司）募投项目"血液制品智能工厂（一 期）建设项目"的正常实施情况下，公司于2025年10月27日召开第八届董事会第 十六次会议和第八届监事会第十三次会议，审议通过《关于使用部分闲置募集资 金进行现金管理的议案》，公司拟使用不超过人民币60,000.00万元的闲置募集资 金进行现金管理，以实现资金收益，上述额度可滚动使用，管理期限自董事会审 议通过之日起12个月内有效。公司监事会对该事项发表了意见，保荐人出具了核 查意见。现将有关情况公告如下： 华润博雅生物制药集团股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准博雅生物制药集团股份有限公司非公 开发行股票的批复》（证监许可[2018]117号）核准，公司向4名特定投资者非公 开发行股票32,247,662股，发行价格为31.01元/ ...

本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、召开会议基本情况 （一）大会届次：2025 年第二次临时股东会。 （二）会议召集人：公司董事会。（经公司第八届董事会第十六次会议审议 通过，决定召开本次股东会） 证券代码：300294 证券简称：博雅生物 公告编号：2025-078 华润博雅生物制药集团股份有限公司 关于召开 2025 年第二次临时股东会的通知 （三）会议召开的合法、合规性：召集程序符合有关法律、行政法规、部门 规章、规范性文件和《公司章程》的规定。 （四）会议召开时间：2025 年 11 月 13 日下午 14:00。 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 11 月 13 日上午 9:15-9:25，9:30-11:30，下午 13:00—15:00；通过互联网投票 系统投票的时间为 2025 年 11 月 13 日上午 9：15—下午 15:00 期间的任意时间。 （五）会议召开方式：现场投票和网络投票相结合的方式。 现场投票：股东本人出席现场会议或通过授权委托书（见附件 2）委托他人 出席； 网络投票：公 ...

Core Viewpoint - The blood products industry continues to face challenges, as evidenced by the financial performance of TianTan Biological Products Co., Ltd. in its Q3 2025 report, which shows a decline in net profit despite revenue growth [1][4]. Financial Performance - For the first three quarters of 2025, TianTan reported revenue of approximately 4.465 billion yuan, a year-on-year increase of 9.62%, while net profit attributable to shareholders was about 819 million yuan, a decrease of 22.16% [1][2]. - In Q3 alone, the company achieved revenue of approximately 1.355 billion yuan, up 9.96% year-on-year, but net profit fell to about 186 million yuan, down 42.84% [1][2]. Profitability Metrics - The gross profit margin for the first three quarters was 43.81%, down from 45.4% in the first half of the year, indicating a downward trend [2][3]. - The company experienced a significant decline in cash flow from operating activities, with a net cash flow of 117 million yuan for the first three quarters, a 91% decrease year-on-year [3]. Industry Context - The blood products industry is under pressure, with many companies reporting declining profits due to factors such as falling product prices, increased market competition, and changes in policy [4]. - Despite the current challenges, the blood products sector is recognized for its essential nature and resource-based characteristics, suggesting potential long-term stability [4].

证券代码：300294 证券简称：博雅生物 公告编号：2025-069 华润博雅生物制药集团股份有限公司 关于持股5%以上股东部分股份质押及解除司法冻结的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司）近日收到 5%以上股 东深圳市高特佳投资集团有限公司（以下简称高特佳集团）出具的《关于部分股 份质押及解除司法冻结的告知函》，获悉高特佳集团将所持有公司的部分股份进 行质押及部分股份解除司法冻结，具体事项如下： 一、股东股份质押基本情况 （一）股东本次股份质押基本情况 2025 年 10 月 21 日，高特佳集团将其持有公司的无限售条件流通股 1,855,369 股（占公司总股本的 0.37%）质押给苏州诚河清洁设备有限公司进行融资，具体 情况如下： | | 是否为 | | | | | 是 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股 | 控股股 | | | | 是否为 | 否 | | 质 | | ...

Core Viewpoint - The company is making steady progress on its C1 esterase inhibitor research project and aims to enhance its product structure and core competitiveness through increased R&D efforts [1] Summary by Categories R&D Progress - The C1 esterase inhibitor is progressing smoothly according to the company's statement on the investor interaction platform [1] - The company plans to accelerate the new product launch process as part of its strategy to broaden its product structure [1] Future Expectations - The company acknowledges that the development and approval of new products is a lengthy and high-risk process, indicating that there are uncertainties involved [1] - The company will provide timely updates based on the progress of product development [1]

Group 1 - The company emphasizes its commitment to aligning its operational strategies with strategic goals, considering the policy and market environment [1] - The company aims to enhance its management practices to effectively safeguard the rights and interests of shareholders and the company itself [1]

2025年10月17日，科创板将迎来一只受市场关注的医药创新股——必贝特（787759）。在"生物+小核酸/RNAi技术"备受资金追捧的背景下，这家公司被认 为是医药赛道中一个"潜力试金石"。但创新药本身就充满不确定性：高投入、长周期、审批风险，各类变量都能打乱预期。本文从业务定位、行业趋势、 可比对标、中签策略、风险警示、首日预测等维度，帮助你在打新决策中更加沉着冷静。 一、申购框架 & 公司基本面速览 • 发行/申购安排 必贝特本次拟公开发行9,000万股，占发行后总股本约20%。网上发行数量为1,440万股（约16%），申购代码为787759，发行价定为¥17.78元/股。 单户网上申购上限为14,000股（对应市值约14.0万元），顶格申购需持有沪市市值约14万元。 2024年归属于母公司股东的净亏损约¥5,599.83万元；2023年亏损更大。 公司资产负债率相对温和，杠杆压力相对可控。 观点总结：作为典型的创新药公司，盈利尚不可期，关键在于未来研发能否落地与商业化路径是否顺畅。 • 主业定位 & 技术路径 公司聚焦肿瘤、自身免疫病、代谢性疾病等领域的小核酸/siRNA平台+化学药布局。 其公开资料 ...

Core Insights - On October 15, Boya Bio's stock increased by 0.08%, with a trading volume of 63.16 million yuan [1] - The company reported a financing net purchase of 2.14 million yuan on the same day, with a total financing balance of 671 million yuan [1][2] - Boya Bio's main business revenue composition includes 84.58% from blood products, 8.63% from biochemical drugs, and 6.12% from distribution [1] Financing and Trading Activity - On October 15, Boya Bio had a financing buy amount of 10.86 million yuan and a financing repayment of 8.72 million yuan, resulting in a net financing purchase of 2.14 million yuan [1] - The current financing balance of 669 million yuan accounts for 5.35% of the circulating market value, indicating a high level compared to the past year [1] - The company had a securities lending balance of 2.34 million yuan, with a lending volume of 94,400 shares, also reflecting a high level compared to the past year [1] Shareholder and Financial Performance - As of September 30, Boya Bio had 30,200 shareholders, an increase of 0.32% from the previous period, with an average of 16,694 circulating shares per person, a decrease of 0.32% [2] - For the first half of 2025, Boya Bio achieved an operating income of 1.008 billion yuan, a year-on-year increase of 12.51%, while the net profit attributable to shareholders decreased by 28.68% to 225 million yuan [2] - The company has distributed a total of 1.007 billion yuan in dividends since its A-share listing, with 489 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder, holding 27.04 million shares, a decrease of 800,100 shares from the previous period [3] - The sixth-largest circulating shareholder, China Merchants Guozhen Biomedicine Index A, held 5.09 million shares, down by 512,100 shares [3] - Notably, the E Fund Growth Enterprise Board ETF and GF Healthcare Stocks A have exited the top ten circulating shareholders list [3]

Core Insights - The appointment of Cheng Jie as the new president of China Resources Pharmaceutical signifies a strategic shift as the company faces challenges in traditional business growth and profitability amidst industry transformation [1][2][11] - The company reported a "revenue growth without profit increase" in its recent half-year report, with total revenue reaching 131.87 billion yuan, a 2.5% year-on-year increase, while net profit dropped by 20.3% to 2.08 billion yuan [2][7] - Cheng Jie, who has a strong background within the company, is expected to leverage his experience to navigate the current challenges and drive innovation and growth [4][19] Company Performance - China Resources Pharmaceutical's revenue has shown steady growth, increasing from 232.20 billion yuan in 2022 to 257.67 billion yuan in 2024, with an average annual growth rate of over 5% [7] - However, net profit has fluctuated, with a 13.06% decline in 2024 to 3.35 billion yuan and a further drop of 20.25% in the first half of 2025 [7][8] - The decline in profit is attributed to one-time impairment losses and rigid expense growth, with a net loss of 1.09 billion yuan in other income and losses reported for the first half of 2025 [7][8] Strategic Initiatives - The company has been actively pursuing mergers and acquisitions, with significant transactions including the acquisition of 100% of Green Cross Hong Kong for 1.82 billion yuan and a 28% stake in Tian Shi Li Pharmaceutical for 6.21 billion yuan [9][10] - Despite the expansion through acquisitions, the company is now shifting focus towards optimizing its asset structure by divesting non-core and loss-making businesses to enhance operational efficiency and profitability [10][15] - Cheng Jie is tasked with balancing the expansion from acquisitions with the need for profit growth, as well as addressing potential impairment risks associated with goodwill from these acquisitions [11][19] Industry Context - The Chinese pharmaceutical distribution market is experiencing maturation and differentiation, presenting structural opportunities for leading companies like China Resources Pharmaceutical [12] - Collaborations with multinational pharmaceutical companies are increasing, as these companies seek to focus on core products and leverage local distribution expertise [12][13] - The industry is transitioning from a phase of scale expansion to one of high-quality development, emphasizing the need for new products, channels, and innovative service models [14][15] Innovation and R&D - China Resources Pharmaceutical is enhancing its pharmaceutical business through initiatives such as establishing a 1 billion yuan investment fund focused on innovative drugs and high-end medical devices [17] - The company is also pursuing partnerships for innovative drug development, such as a collaboration with Nanjing Ai Er Pu for a heart failure treatment [17][19] - However, the company faces challenges in its R&D efforts, with a significant portion of its pipeline still focused on generic drugs rather than innovative products, which may hinder its competitive edge in a rapidly evolving market [18][19]